150 related articles for article (PubMed ID: 16094088)
1. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
Mehraban D; Esfahani F
J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088
[No Abstract] [Full Text] [Related]
2. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
3. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46.
Ooi WL; Stockler M; Hayne D
Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685
[No Abstract] [Full Text] [Related]
4. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.
Ali-El-Dein B; Nabeeh A; Ismail EH; Ghoneim MA
J Urol; 1999 Aug; 162(2):339-42. PubMed ID: 10411034
[TBL] [Abstract][Full Text] [Related]
5. Editorial comment to Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Mostafid H
Int J Urol; 2010 Sep; 17(9):766-7. PubMed ID: 20727047
[No Abstract] [Full Text] [Related]
6. Maintenance intravesical bacillus Calmette-Guérin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group.
Koga H; Ozono S; Tsushima T; Tomita K; Horiguchi Y; Usami M; Hirao Y; Akaza H; Naito S;
Int J Urol; 2010 Sep; 17(9):759-66. PubMed ID: 20604814
[TBL] [Abstract][Full Text] [Related]
7. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.
Sylvester RJ; van der Meijden AP; Witjes JA; Kurth K
J Urol; 2005 Jul; 174(1):86-91; discussion 91-2. PubMed ID: 15947584
[TBL] [Abstract][Full Text] [Related]
8. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R
J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394
[TBL] [Abstract][Full Text] [Related]
9. Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73.
Cai T; Luciani LG; Malossini G
Eur Urol; 2010 Jun; 57(6):e57; author reply e58-9. PubMed ID: 20227819
[No Abstract] [Full Text] [Related]
10. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial.
van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R;
J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ
Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157
[TBL] [Abstract][Full Text] [Related]
12. Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci, E. Zini, N. Mondaini, v. Boddi, s. Mazzoli and R. Bartoletti J Urol 2008; 180: 110-115.
Sylvester RJ; Oosterlinck W; O'Donnell M
J Urol; 2009 Jan; 181(1):410. PubMed ID: 19010500
[No Abstract] [Full Text] [Related]
13. Prostatorectal fistula following intravesical bacillus Calmette-Guérin immunotherapy for carcinoma in situ of the urinary bladder.
Enatsu N; Ota T; Ochi A
Int J Urol; 2010 Sep; 17(9):822-3. PubMed ID: 20727055
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
[TBL] [Abstract][Full Text] [Related]
15. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56.
Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R
Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768
[No Abstract] [Full Text] [Related]
16. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
17. Re: Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial.
Inman BA
J Urol; 2006 May; 175(5):1960; author reply 1960-1. PubMed ID: 16600806
[No Abstract] [Full Text] [Related]
18. Re: Agarwal a et al.: The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma (Urology 2007;70:1075-1078).
Agrawal MS; Bansal S
Urology; 2009 Feb; 73(2):450-1. PubMed ID: 19185768
[No Abstract] [Full Text] [Related]
19. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
[TBL] [Abstract][Full Text] [Related]
20. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation.
Takayama H; Nishimura K; Tsujimura A; Nakai Y; Nakayama M; Aozasa K; Okuyama A; Nonomura N
J Urol; 2009 Apr; 181(4):1894-900. PubMed ID: 19237175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
